Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
Primary Purpose
Obesity
Status
Unknown status
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
oleoyl-estrone (MP 101)
Sponsored by

About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- Be a male or female between the ages of 18 and 65 years, inclusive
- Female subjects must be either surgically sterile or at least 2 years postmenopausal
- Have a BMI of 27 - 38.9, inclusive
- Have a stable weight for the past 30 days per subject report
- Be otherwise healthy and have an acceptable medical history
- Have negative urinalysis test results for drugs of abuse and alcohol
- Have the ability to understand the requirements of the study, have provided written informed consent and agree to abide by the study restrictions
- Exhibit stable behavior patterns with regard to smoking and exercise
- Subject who has at least one factor of the metabolic syndrome
Exclusion Criteria:
- Be pregnant or nursing
- Have taken exclusionary medication in the past 30 days
- Have any clinically significant abnormal laboratory test as determined by the investigator
- Have a clinically significant illness during the 30 days before enrollment
- Have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV
- Have a confirmed diagnosis or history of cancer, with the exception of nonmelanoma skin cancer
- Have a previous diagnosis of diabetes
- Be otherwise unsuitable for the study, in the opinion of the investigator
- Have an allergy to safflower seeds or its byproducts (e.g., safflower oil)
- Have any postmenopausal bleeding within the last 6 months
- Have been involved in a formal or informal (self-imposed) diet regimen within the last 30 days
- Currently working night shifts
- Have a history of known multiple miscarriages
Sites / Locations
- Pennington Biomedical Research
- Jean Brown Research
- Swiss Pharma Contract
Outcomes
Primary Outcome Measures
To evaluate the safety and tolerability
Secondary Outcome Measures
To evaluate the preliminary efficacy
Full Information
NCT ID
NCT00449202
First Posted
March 16, 2007
Last Updated
March 16, 2007
Sponsor
Manhattan Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00449202
Brief Title
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
Official Title
A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
March 2007
Overall Recruitment Status
Unknown status
Study Start Date
June 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Manhattan Pharmaceuticals
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
100 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
oleoyl-estrone (MP 101)
Primary Outcome Measure Information:
Title
To evaluate the safety and tolerability
Secondary Outcome Measure Information:
Title
To evaluate the preliminary efficacy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Be a male or female between the ages of 18 and 65 years, inclusive
Female subjects must be either surgically sterile or at least 2 years postmenopausal
Have a BMI of 27 - 38.9, inclusive
Have a stable weight for the past 30 days per subject report
Be otherwise healthy and have an acceptable medical history
Have negative urinalysis test results for drugs of abuse and alcohol
Have the ability to understand the requirements of the study, have provided written informed consent and agree to abide by the study restrictions
Exhibit stable behavior patterns with regard to smoking and exercise
Subject who has at least one factor of the metabolic syndrome
Exclusion Criteria:
Be pregnant or nursing
Have taken exclusionary medication in the past 30 days
Have any clinically significant abnormal laboratory test as determined by the investigator
Have a clinically significant illness during the 30 days before enrollment
Have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV
Have a confirmed diagnosis or history of cancer, with the exception of nonmelanoma skin cancer
Have a previous diagnosis of diabetes
Be otherwise unsuitable for the study, in the opinion of the investigator
Have an allergy to safflower seeds or its byproducts (e.g., safflower oil)
Have any postmenopausal bleeding within the last 6 months
Have been involved in a formal or informal (self-imposed) diet regimen within the last 30 days
Currently working night shifts
Have a history of known multiple miscarriages
Facility Information:
Facility Name
Pennington Biomedical Research
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
Jean Brown Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States
Facility Name
Swiss Pharma Contract
City
Basel
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
We'll reach out to this number within 24 hrs